Abstract: A preservative-free ophthalmic pharmaceutical emulsion includes a nitric oxide-donating prostaglandin F2? derivative or a pharmaceutically acceptable salts or esters thereof as an active ingredient. A method applies promoting blood velocity of optic nerve head (ONH) for treating glaucoma patients and lowering risks for open angle glaucoma and retinal ischemia disease, such as retinal vein occlusion (RVO), including central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO), and retinal artery occlusion (RAO), including central retinal artery occlusion (CRAO) and branch retinal artery occlusion (BRAO).

Abstract: Embodiments herein include methods and constructs that can be used to co-express two or more polypeptides of interest from a single polynucleotide encoding a precursor polypeptide. Within this precursor polypeptide can reside at least one autonomous processing unit, which can mediate release of flanking polypeptides of interest in cis. The processing unit can include an N-terminal autocatalytic cleavage domain and a C-terminal cleavage domain. Some embodiments include constructs and methods for co-expressing polypeptides without N- or C-terminal overhangs, in any cellular or extracellular location, and/or in stoichiometric ratios.

Abstract: The present invention relates to methods and compositions to detect analytes in a sample using antibody molecules that are transformed into nanoscale “self-signaling” biosensors. It relates in particular to those methods and compositions that provide for single-step detection of target analytes without the need for labor-intensive steps necessary in conventional assays.

Abstract: The present invention relates to methods and compositions to detect analytes in a sample using antibody molecules that are transformed into nanoscale “self-signaling” biosensors. It relates in particular to those methods and compositions that provide for single-step detection of target analytes without the need for labor-intensive steps necessary in conventional assays.

Abstract: Sensor constructs for detecting the presence of an analyte in a sample comprising a molecular scaffold, a pair of labels which interact via Förster resonance energy transfer, and at least one molecular recognition domain for binding the analyte. A changed optical signal is produced when the analyte is bound by the molecular recognition domain.

Abstract: Sensor constructs for detecting the presence of an analyte in a sample comprise a molecular scaffold, a pair of labels which interact via Förster resonance energy transfer, and at least one molecular recognition domain. When the analyte is bound by the molecular recognition domain, the Förster resonance energy interaction between the pair of labels is disrupted, resulting in a changed optical signal.

Abstract: This invention is in the field of recombinant Plasmodium falciparum polypeptides and relates to recombinant or synthetic antigen compositions which comprise p42 antigens, and more specifically to methods and compositions for the expression of Plasmodium falciparum polypeptides in transgenic plants.

Abstract: Sensor constructs for detecting the presence of an analyte in a sample comprise a molecular scaffold, a pair of labels which interact via Förster resonance energy transfer, and at least one molecular recognition domain. When the analyte is bound by the molecular recognition domain, the Förster resonance energy interaction between the pair of labels is disrupted, resulting in a changed optical signal.

Abstract: This invention is in the field of recombinant Plasmodium falciparum polypeptides and relates to recombinant or synthetic antigen compositions which comprise p42 antigens, and more specifically to methods and compositions for the expression of Plasmodium falciparum polypeptides in transgenic plants.